Resveratrol solid lipid nano-particles and preparation method thereof

Abstract

The invention relates to resveratrol solid lipid nano-particles and a preparation method thereof. The preparation method comprises the following steps: (a) weighing resveratrol, an emulsifying agent and a lipid material, heating and melting the lipid material, then uniformly mixing with the emulsifying agent and resveratrol, then adding into an organic solvent, and uniformly mixing to obtain an oil phase; and (b) putting the oil phase into a container, distilling at reduced pressure to obtain an oil film, putting a water phase into the container, and also treating in an ultrasonic cleaner of which the ultrasonic power is 40-60 KHz for 30-60 minutes to obtain the resveratrol solid lipid nano-particles. The resveratrol solid lipid nano-particles prepared by using the method disclosed by the invention have the advantages of small particle sizes, high medicine loading capacity, high medicine absorption speed, high bioavailability, convenience in taking and small toxicity, and have strong practicability.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a resveratrol solid lipid nanoparticle and a preparation method thereof. Background technique [0002] Many studies have reported that resveratrol (Resveratrol, Res) is a polyphenolic compound that has pharmacological effects such as lowering blood lipids, protecting cardiovascular, anti-tumor, and anti-oxidation. Studies have found that resveratrol also has the ability to inhibit the release of calcium stores. Calcium ions thus inhibit platelet activity and play a role in inhibiting platelet aggregation. Resveratrol has strong polarity, is difficult to dissolve in water, and is easily soluble in strong polar solvents such as chloroform, methanol, ethanol, acetone, etc. It has low oral bioavailability and is unstable to light. inconvenient. Solid Lipid Nanopartieles (SLN) is a solid micelle drug delivery system made by using physiologically compatible high-melting point lipid ...

AI Technical Summary

Problems solved by technology

Wherein, wine agent (public patent No. CN1472303) is suitable for a smaller crowd, injection (public patent No. CN102188370A) has poor patient compliance, and phospholipid complex (public patent No. CN101095664) has poor stability, so the above dosage forms are not suitable for clinical use

Liposome (public patent No. CN102757555A) has a complicated preparation process and is not suitable for large-scale industrial production, so it is also not suitable for clinical use

[0004] There is no report about resveratrol solid lipid nanoparticles

Images